Skip Ribbon Commands
Skip to main content


Liver disease and the rise of hepatitis due to the opioid crisis were just a few of the discussion topics when James Trotter, MD – Medical Director, Transplant Hepatology at Baylor University Medical Center met in Washington D.C.  with Rep. Pete Sessions from the 32nd Congressional district.  Dr. Trotter is part of a team of physicians and patients who participated in Capitol Hill Day with other AASLD (American Association for the Study of Liver Disease) members to promote legislative initiatives for liver patients.  Dr. Trotter says the impact of doctors and patients meeting with lawmakers could be effective in maintaining funding for research and gaining support for extended insurance coverage for living donors.  


New Medicine Could Melt Away Fat

James Trotter, MD, Medical Director, Transplant Hepatology at Baylor University Medical Center is one of the chief investigators of a new therapy that could revolutionize how fatty liver disease is managed.   According to the American Liver Foundation, 60 million Americans are living with nonalcoholic steatoheaptitis (NASH) which is a part of a group of conditions that lead to fat buildup in the liver, inflammation and fibrosis.  Early results were just published in The Lancet, one of the highest ranked medicine journals in the world. 


Baylor leads the way in studies to combat the toll of fatty liver disease

Liver disease is on the rise among middle-aged Americans.  The Centers for Disease Control and Prevention (CDC) reports that fatty liver disease, viral hepatitis, and alcoholic liver disease are the major contributors to a rise in liver-disease-related deaths and liver cancer in people ages 45-64.   Teen-idol David Cassidy died in 2017 of alcohol related liver disease and his death is just one example of the risks of liver disease in his particular age group. 


Novel Technology Reduces Need for Liver Biopsies

Detecting and staging hepatic fibrosis is important in the treatment of chronic liver diseases that can progress to cirrhosis.  Liver biopsy is the standard method of detecting and staging fibrosis but a new, noninvasive alternative is now in use at Baylor University Medical Center at Dallas (BUMC) and Baylor Scott & White All Saints Medical Center – Fort Worth (BSWASMC).  Ultrasound (US) based liver elastography has replaced the need for liver biopsy for many liver disease patients and decreased the number of biopsies by 90%. 


Living Donor Study: Reducing barriers to living donor transplantation

Baylor University Medical Center is one of 16 sites nationwide participating in a pilot study to determine how living donor transplant candidates fare after transplant, whether they actually donate or not.  There are six liver transplant sites, including Baylor,  and ten kidney programs participating in the study. 


Liver Outreach clinics continue to expand

Patients with liver disease who live miles from Baylor University Medical Center (BUMC) and Baylor Scott & White All Saints Medical Center – Fort Worth (BSWASMC) benefit greatly from having access to liver outreach clinics in their communities.  Volumes continue to increase at the nine current liver outreach clinics.  As a result, hepatologists on staff at BUMC and BSWASMC are increasing the number of days they are available to see patients in outreach.  Patients can be referred to a liver outreach clinic for a wide variety of liver diseases, including hepatitis, fatty liver disease, cirrhosis, and autoimmune hepatitis, to name a few.  The Waxahachie outreach clinic, managed by transplant hepatologist, Sumeet Asrani, MD  is now open twice a month.  In addition, the Odessa outreach clinic where transplant hepatologist, Apurva Modi, MD sees patients is open for appointments twice monthly.  Check back frequently for updates on new outreach clinic sites.  ​​

Non-alcoholic Fatty Liver Disease or NAFLD

The Spectrum of NAFLD: Elevated Liver Tests, Cirrhosis and Liver Cancer Estimates show that 20 to 30 percent of the U.S. population has non-alcoholic fatty liver disease or NAFLD. NAFLD is a broad term used to describe a spectrum of liver diseases with evidence of steatosis (or fat) in the liver once other causes of […]


New Hepatitis C Drugs, Sofosbuvir and Simeprevir

Newly Approved Drugs Show High Cure Rates for Hepatitis C Two new drugs are providing hope to the approximately 3.2 million people in the United States who are infected with the hepatitis C virus. Unlike the previous therapy, the new drugs have minimal side effects and offer most patients an almost 90 percent chance at […]


Hepatic Elastography and Liver Disease

MR-based hepatic elastography involves mechanical stimulation of the liver to determine liver stiffness, which can be used as an index for how much fibrosis is present. Baylor University Medical Center at Dallas is one of the few medical centers in the nation to offer this advanced imaging technology.


Transplant Hepatology Fellowship Program

The liver transplant program at the Annette C. and Harold C. Transplant Institute at Baylor University Medical Center at Dallas and Baylor All Saints Medical Center at Fort Worth is the fifth largest in the United States. More than 100 liver transplants are performed annually. The surgical team is lead by Dr. Goran Klintmalm and […]


Hepatitis C, a Silent Killer, Meets Its Match

New York Times, November 4, 2013 Medicine may be on the brink of an enormous public health achievement: turning the tide against hepatitis C, a silent plague that kills more Americans annually than AIDS and is the leading cause of liver transplants. If the effort succeeds, it will be an unusual conquest of a viral […]


New Hepatitis C Treatment

There are 3 million Americans infected with Hepatitis C, and three out of four of them are baby boomers. Most of them contracted the disease without knowing it. But there is a new treatment that was just approved by the FDA. Dr. Jacqueline O’Leary discusses in the video below.


Clinical Studies

Our team of hepatologists play an integral role in the development of select clinical studies of approved antiviral medications to treat hepatitis C and hepatitis B. More than 40 drug trials designed to treat or cure the hepatitis C virus are currently underway at Baylor Dallas and Baylor Fort Worth. For more information regarding clinical […]


Incidence of Liver Disease Underestimated

According to the National Center for Health Statistics (NCHS), chronic liver disease and cirrhosis is the 12(th) leading cause of death in the United States. However, this single descriptor might not adequately enumerate all deaths from liver disease. The aim of our study was to update data on liver mortality in the United States. Read […]